| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
An anti-bone-resorptive drug Denosumab, an anti-RANKL antibody, is used to treat adults' bone disease because of its inhibitory effect of osteoclast differentiation. However, the precise effect of anti-RANKL antibody in younger patients are unknown. In the present study, we analyzed the effect of anti-RANKL antibody on growth and bone metabolism in young mice. Newborn mice exposed to the antibody in utero were normally born, but died within 24 h after birth. Mice, which were treated with anti-RANKL antibody at 1-week-old, showed decreased osteoclastogenesis and increased bone mass at the age of 2 weeks. However, at the age of 8 weeks, mice showed normal body length, body weight and tooth development. These results suggest that an anti-RANKL antibody is safety and efficacious in young patients.
|
